Sessa Capital IM L.P. Grows Position in Sotera Health (NASDAQ:SHC)

Sessa Capital IM L.P. increased its position in Sotera Health (NASDAQ:SHC - Free Report) by 46.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,300,597 shares of the company's stock after buying an additional 2,000,000 shares during the period. Sotera Health accounts for about 3.9% of Sessa Capital IM L.P.'s investment portfolio, making the stock its 10th biggest position. Sessa Capital IM L.P. owned about 2.22% of Sotera Health worth $105,220,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Sotera Health by 27.0% during the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company's stock valued at $145,863,000 after buying an additional 2,579,248 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Sotera Health by 24.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 27,584 shares of the company's stock worth $331,000 after purchasing an additional 5,400 shares during the period. American International Group Inc. increased its position in shares of Sotera Health by 23.2% during the 1st quarter. American International Group Inc. now owns 165,338 shares of the company's stock valued at $1,986,000 after purchasing an additional 31,124 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Sotera Health during the 1st quarter valued at $258,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in Sotera Health by 25.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 59,480 shares of the company's stock valued at $715,000 after buying an additional 12,195 shares during the period. 91.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SHC shares. Royal Bank of Canada reissued an "outperform" rating and issued a $17.00 target price on shares of Sotera Health in a research note on Thursday. Barclays upped their price target on shares of Sotera Health from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, August 6th. Finally, Citigroup boosted their target price on Sotera Health from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Sotera Health has an average rating of "Moderate Buy" and a consensus price target of $16.50.

Sotera Health Trading Up 3.1 %

SHC stock traded up $0.39 during mid-day trading on Friday, reaching $12.80. The company had a trading volume of 2,087,125 shares, compared to its average volume of 1,316,874. The company has a market capitalization of $3.63 billion, a PE ratio of 49.64 and a beta of 2.08. The firm has a 50 day moving average of $15.69 and a 200 day moving average of $13.93. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.44. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $0.18 EPS. On average, equities analysts predict that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now owns 49,215,301 shares of the company's stock, valued at approximately $739,705,974.03. This represents a 16.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 55.12% of the company's stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.